BPC-157 is one of the most recognised names in peptide research, usually discussed in relation to gut protection, tissue repair, tendon and ligament models, inflammation and recovery. Its origins, however, are more specific than its modern reputation suggests.
The compound began with research into the stomach’s own protective systems. That history matters because it explains both the interest in BPC-157 and the limits of what can responsibly be claimed about it today.
What is BPC-157?
BPC-157, also known as Pentadecapeptide BPC 157, is a synthetic peptide made up of 15 amino acids. It is derived from a partial sequence of a body protection compound reported in human gastric juice.
The word pentadecapeptide simply means a peptide with 15 amino acids. The sequence associated with BPC-157 is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val.
In research settings, BPC-157 is widely explored for cytoprotection, gastrointestinal lining protection, wound and tissue repair, angiogenesis, collagen synthesis and inflammatory signalling. It is not an established mainstream medicine, and most of the better-known findings come from laboratory and animal work rather than large controlled human trials.
Why the stomach was the starting point
The early scientific interest around BPC-157 grew out of cytoprotection, which refers to mechanisms that protect cells and tissues from damage.
The stomach is an obvious place to investigate this. Its lining is constantly exposed to acid, digestive enzymes and other potentially damaging substances, yet it normally protects and repairs itself well. Researchers wanted to understand whether gastric tissue contained natural substances involved in that protection.
A research group led by Professor Predrag Sikirić at the University of Zagreb in Croatia became closely associated with this area. Their work helped shape the concept of Body Protection Compound, or BPC, and later the 15-amino-acid fragment now known as BPC-157.
How BPC-157 entered peptide research
One key point in BPC-157’s history is 1993, when Sikirić and colleagues described a gastric-juice peptide called BPC and identified the active 15-amino-acid fragment that became BPC-157.
The discovery drew attention partly because many peptides are unstable in the gastrointestinal tract. Enzymes and acidic conditions can break them down quickly. BPC-157 was reported to be unusually stable in gastric juice, which made sense given the gastric environment in which the original compound was studied.
This reported stability helped widen interest in the compound. Early work focused on gastric lesions, ulcer models, intestinal injury, inflammation, alcohol-related gastric damage and NSAID-related gastrointestinal damage. Later research expanded well beyond the stomach.
From gastric protection to tissue repair
BPC-157’s modern reputation is largely linked to repair-related models. In the 1990s and 2000s, researchers began examining the peptide in experimental settings involving wounds, tendons, ligaments, muscle, bone, blood vessels and nerves.
The reference profile for BPC-157 describes it as an extensively studied synthetic peptide renowned in laboratory contexts for tissue repair, inflammation reduction and gastrointestinal protection capabilities. Proposed mechanisms include angiogenesis, enhanced collagen synthesis, modulation of growth factor expression including VEGF, and protection against tissue damage through localised or systemic delivery pathways.
That does not mean all of these effects have been proven in humans. It means the compound has become a broad research tool across several preclinical models.
Key research areas for BPC-157
BPC-157 is most often discussed across three overlapping research areas: wound and soft-tissue healing, gastrointestinal protection and neurological injury models.
Research areaWhat BPC-157 is explored forEvidence contextWound healingTendon-to-bone healing, ligament models, muscle injury, angiogenesis and collagen-related repair processesMost prominent in animal and laboratory modelsGastrointestinal researchGastric and duodenal ulcer protection, intestinal repair, mucosal barrier function and epithelial regenerationClosely linked to the compound’s original gastric-protection historyNeurological modelsNeuroprotection, spinal cord injury models and peripheral nerve regenerationModerate and largely preclinical research interest
The nitric oxide and angiogenesis connection
One reason BPC-157 became interesting beyond gut research was its apparent interaction with the nitric oxide system. Nitric oxide is involved in blood-vessel function, circulation and signalling.
By the late 1990s, experiments were examining how BPC-157 interacted with changes in nitric oxide activity, including effects on gastric integrity and blood pressure in experimental models. Later work focused more closely on blood-vessel formation, endothelial function and tissue circulation.
The peptide profile also highlights VEGF-related signalling and VEGFR2 activation as part of the angiogenesis discussion. This is one proposed explanation for why BPC-157 has been explored in wound healing and tissue repair models.
What the research timeline shows
The history of BPC-157 is unusual because experimental interest has remained active for more than three decades, while human clinical evidence has stayed limited.
PeriodResearch developmentEarly 1990sResearchers investigate protective compounds associated with gastric tissue and gastric juice.1993BPC and the 15-amino-acid BPC-157 fragment are described in scientific literature.Late 1990sResearch expands into wound healing, inflammation, organ protection and nitric oxide signalling.1999A review of BPC-157 pharmacological properties reflects the growing experimental literature.2000s and 2010sAnimal research expands into tendons, ligaments, muscle, bone, blood vessels, nerves and gastrointestinal tissue.TodayBPC-157 remains an investigational peptide with far more preclinical work than published human evidence.
If you’re researching BPC-157 and want to compare peptide prices in the SA, start here: PeptideSupermarket®’s peptide price comparison page
Selected findings from the BPC-157 research profile
The supplied research profile lists several notable areas of investigation. These should be read as research findings from specific models, not as treatment claims for people.
2003 Achilles tendon healing research: Reported improved tendon healing, biomechanical properties and tendon-to-bone integration in rat models.
2006 muscle healing research: Explored quadriceps healing in rat models, with reported improvements in histology, inflammation markers and function.
2017 VEGF and angiogenesis study: Examined pro-angiogenic effects via VEGFR2 activation, offering one possible mechanism for wound-healing observations.
2019 spinal cord injury research: Reported functional recovery and reduced tissue damage in rat models.
2020 gastric ulcer protection research: Focused on cytoprotective effects against gastric ulcers through multiple protective mechanisms.
2020 safety evaluation: Reported no serious adverse effects at studied therapeutic doses up to 1000 micrograms per kilogram for 90 days, within that research context.
Human evidence remains the major gap
BPC-157 has a large preclinical footprint, but the human evidence base is much smaller. Historical literature refers to human clinical development under names including PL-10, PLD-116 and PL 14736, particularly in gastrointestinal research. More recent small human investigations have also appeared.
A recent FDA review identified several small human studies involving different administration routes and emphasised limitations in the available safety information.
The practical takeaway is simple: BPC-157 has been extensively explored experimentally, but its effects, risks and reproducibility in humans have not been established to the same standard as its reputation might imply.
Safety considerations in research discussions
The BPC-157 profile lists mild injection-site redness, injection-site irritation and possible mild digestive adjustment with oral use as common reported issues. It also lists stop signs such as persistent injection-site reactions, signs of infection, unusual swelling or rash, severe headaches or dizziness, allergic reactions and persistent or worsening digestive issues.
Contraindications noted in the profile include active cancer because of angiogenic effects, pregnancy or breastfeeding, blood thinners where medical consultation is relevant due to angiogenesis, and WADA prohibition for competitive athletes.
These points do not establish safety for general use. They are risk considerations that matter when evaluating BPC-157 as an investigational compound.
Why BPC-157 is still discussed today
BPC-157 remains popular in peptide research because it sits at the intersection of several high-interest areas: gut protection, soft-tissue repair, blood-vessel signalling and inflammation models. Its origin in gastric protection gives the compound a coherent scientific starting point, while later animal research explains its broader reputation.
The sensible view is that BPC-157 is a serious research peptide with an unusually wide experimental literature, not a settled answer for human recovery or gastrointestinal conditions. The final chapter depends on stronger human data.
Frequently asked questions
What is BPC-157 used for in research?
BPC-157 is used in laboratory and preclinical research on gastrointestinal protection, wound healing, tendon and ligament models, muscle injury, angiogenesis, inflammation and some neurological injury models.
Is BPC-157 a gut healing peptide?
BPC-157 is often discussed in relation to gut healing because it originated from gastric-protection research and has been studied in gastric ulcer, intestinal repair and mucosal healing models.
Does BPC-157 have strong human evidence?
No. The experimental and animal literature is much larger than the published human evidence. Small human investigations exist, but they do not close the gap between preclinical findings and established human outcomes.
How long is the half-life of BPC-157?
The supplied peptide profile lists BPC-157 as having a half-life of less than 30 minutes. Half-life information should be interpreted within the specific research model and administration context being assessed.
Where can researchers compare BPC-157 prices in South Africa?
Researchers comparing peptides SA suppliers can use PeptideSupermarket’s price comparison page to review options. If you are checking where to buy peptides or looking for a peptide supplier SA, compare pricing and supplier details atPeptide Supermarket's peptide price comparison Research and educational disclaimer
This content is for research and educational purposes only. It is not medical advice, and it does not recommend human consumption, self-administration, diagnosis or treatment with BPC-157.
Final thoughts
BPC-157’s history starts with the stomach, not sports recovery. Its rise came from decades of experimental work on cytoprotection, tissue repair and vascular signalling, while human evidence has remained comparatively limited.
For researchers assessing BPC-157 alongside other peptides, price and supplier transparency matter. Use PeptideSupermarket®’s peptide price comparison page to find the best-value option from listed suppliers.
Compare BPC-157 prices across the UK
Side-by-side prices from every trusted UK supplier stocking BPC-157.
